Related Experiment Video
Updated: Jun 28, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Case Report: Rare Multidrug-Resistant Enterobacter Cloacae Complicated by Invasive Pulmonary Aspergillosis in an
Meili Zhou1, Jinli Shi1, Chunyan Cao1
1Emergency Medical Center, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, People's Republic of China.
Abstract:
Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). We report a rare case of multidrug-resistant (MDR) Enterobacter cloacae pneumonia complicated by invasive pulmonary aspergillosis (IPA) in a 75-year-old male with lung adenocarcinoma who had been receiving osimertinib for 8 months. Prompt susceptibility-guided therapy with polymyxin B plus tigecycline (for MDR bacteria) and voriconazole (for aspergillosis) achieved complete resolution, highlighting the importance of rapid microbiological diagnosis and targeted antimicrobials in this vulnerable population.
Insights
A rare case of multidrug-resistant pneumonia and invasive aspergillosis occurred in a patient on osimertinib treatment for lung cancer. Prompt, targeted antimicrobial therapy led to complete recovery, emphasizing early diagnosis and treatment.
Area of Science:
- Oncology
- Infectious Diseases
- Pulmonology
Background:
- Osimertinib is a standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC).
- Patients with NSCLC receiving targeted therapies may be vulnerable to opportunistic infections.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
11:17Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Pneumonia III: Complications and Assessment
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations